Thanks. As you say, I'm writing for the benefit of

Thanks. As you say, I'm writing for the benefit of people who may not yet have a full understanding of what the true situation is.

I view a stock that has 4 clinical trials in progress for utterly different applications of 3 drugs, ONE for which FDA approval seems extremely likely (Brilacidin for ABSSSI), one which has successfully completed phase 1 and for which further clinical trials for other cancers are being planned, and two of which have had very promising results in animal studies, to be absurdly undervalued with a market cap of a mere 130 million.

This stock could absolutely do something similar to what JAZZ did -- it went from 20 CENTS to 170 DOLLARS in just a few years. It could make fortunes for those who have studied the company and understand what a huge opportunity this is.